Is Pfizer (PFE) Pricing Its Long Term Cash Flow Potential Fairly Today

If you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share ...

Goldman Sachs resets Pfizer stock forecast

Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and ...

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings

Pfizer PFE is set to report its first-quarter 2026 earnings on May 5, before market open. The Zacks Consensus Estimate for ...

Should You Forget Pfizer and Buy This Pharma Stock Instead?

Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) are two pharmaceutical giants that seem to be headed in opposite directions.

Pfizer Could Surprise Again This Earnings Season (Preview)

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer’s ASCO Oncology Data Puts Future Cancer Revenue Story In Focus

Pfizer (NYSE:PFE) is preparing multiple presentations for the upcoming ASCO conference that spotlight new data across its ...
Hosted on MSN

Pfizer Q1 preview follows cancer trial and patent extension

Pfizer will report first-quarter earnings on May 5, with analysts projecting a notable year-over-year drop in profit but a slight revenue increase. The update comes alongside a positive Phase 3 result ...
Morningstar

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration Pfizer won its fight to ...